Prostate cancer screening: what we know and what we need to know.
about
Markers for early detection of cancer: statistical guidelines for nested case-control studiesDifferences between men with screening-detected versus clinically diagnosed prostate cancers in the USAPopulation based prostate cancer screening in north Mexico reveals a high prevalence of aggressive tumors in detected cases.Controversy in clinical cancer screening--prostate-specific antigenScreening for prostate cancer.Current and projected annual direct costs of screening asymptomatic men for prostate cancer using prostate-specific antigen.Prostate-specific antigen testing in Ontario: reasons for testing patients without diagnosed prostate cancer.Screening for cancer. Useful despite its limitationsPromoting informed decision making about prostate cancer screening.A population study of fasting time and serum prostate-specific antigen (PSA) level.Prostate-specific antigen-based screening: controversy and guidelinesThe role of cannabinoids in prostate cancer: Basic science perspective and potential clinical applicationsCost analysis of screening for, diagnosing, and staging prostate cancer based on a systematic review of published studiesProstate cancer, the PSA test and academic detailing in Australian general practice: an economic evaluation.Elevated serum prostate-specific antigen and pancreatic carcinomaAn audit of the investigation and treatment of localised prostatic cancer in the south west region.L-BLP25: a MUC1-targeted peptide vaccine therapy in prostate cancer.Economic evaluation of prostate cancer screening with prostate-specific antigen.Prostate cancer screening. Appropriate choices? Investigators of the American Cancer Society National Prostate Cancer Detection Project.Observations on the early detection of prostate cancer from the American Cancer Society National Prostate Cancer Detection Project.Does educational printed material manage to change compliance with prostate cancer screening?The mammography and prostate-specific antigen controversies: implications for patient-physician encounters and public policy.Design and analysis of cancer screening trials.Ethical issues in clinical trials.Screening for prostate cancer. Is it a service or a disservice?Prostate specific antigen in patients of benign prostate hypertrophy and carcinoma prostate.2-methoxyestradiol Prevents LNCaP Tumor Development in Nude Mice: Potential Role of G2/M Regulatory Proteins.Why is the prostate cancer death rate declining in the United States?Analysis of recent trends in prostate cancer incidence and mortality.African-American males and prostate cancer: assessing knowledge levels in the community.Cancer incidence in Canada: trends and projections (1983–2032).The Language of Stewardship: Is the "Low-Value" Label Overused?Prostate cancer facts and fiction.An image analysis approach for automatic malignancy determination of prostate pathological images.Prostate carcinoma incidence and patient mortality: the effects of screening and early detection.Cancer surveillance series: interpreting trends in prostate cancer--part II: Cause of death misclassification and the recent rise and fall in prostate cancer mortality.Prostate cancer screening: promise and peril--a review.Determining the cause of death in randomized screening trial(s) for prostate cancer.
P2860
Q24804995-FE5C32A1-EDA2-4EDB-AEF7-C30062B80E29Q24805151-B2F5E0F4-C111-42AC-ACD9-A2320FBCBA2DQ33421572-C76D5A04-60F5-46D7-A4D3-0C19B24F3637Q33581984-DF2A8247-89A7-456E-96A9-B1D35257FDF2Q33608384-94061D3D-752D-4588-AB9D-ED4D082D4DEBQ34030359-50795356-3C09-447A-BCCF-155F0D5C2D15Q34030385-5A0B2118-D4DA-47EC-9FAB-A6BE882A3B34Q34181687-2151FFB2-E3A7-4DEF-A0DF-D62418912956Q34378666-75B0FB4F-9116-424E-97E7-BA4B9C003336Q34433274-7C64030A-F000-432A-A663-390B2CCA4BE8Q35211931-0DFC53F1-535C-4B5A-B1AC-38A11D88A3ACQ35921090-07C56C30-25E3-4BCE-A00A-C20E58EE7DE9Q36176742-6EAA6370-EBF9-460A-9DD7-FC200A380004Q36285410-E85287E2-8544-415E-B093-9C3AB058067CQ36680817-D9CE262E-0CFF-4687-8659-A20756108AE6Q36822120-B393790B-91EA-4B39-8F59-168D5214103AQ36981678-CC875ED3-6D48-4329-B83E-4EDD66586A89Q37124961-E4815F32-AA41-4B1D-9B91-E0E1B8A84443Q39370461-584EAB52-31FA-4B6F-802D-FD965876EAA4Q39455194-2C6A3D5A-97E6-4FEB-B2CA-BA937A507C47Q39843486-0C16F2DC-E722-4FFF-A896-E81AE406B2E4Q40402677-15BA3DA0-BA7D-4C4E-BF43-6B4534BC035BQ40446065-149BFE95-AE37-4688-ADD1-794598FBECA2Q40931517-FD494CF5-42EA-47FB-8B31-1A85E11B516BQ41104335-2C076A20-E148-451B-908B-8743B83A6BF0Q41976110-CE635C7C-33FF-494F-B958-89075870B690Q42417939-D5A32C12-CCA5-41F9-AB6B-022F4D7C9853Q44123210-C3F53FE4-4FB3-4570-B5B7-B4EED626F637Q44479197-C7ED28EC-BCCD-48A8-813A-17EFD0BC1C31Q46225762-08CAB953-C553-4DC2-822A-E10C9D8F8A1BQ46495297-069390C0-DDC3-4781-9CA1-A3CE69A535A8Q47159272-1071DF5E-9AAD-4D58-88AA-E069E06D9B91Q50627323-F195D9E9-50B3-4E2C-9A1D-E7F9E9C25B7AQ51068340-EBB51223-4BE9-498C-BFC8-A530926BA671Q52898226-1C5FA1F3-17DA-47BE-844F-E57CF05BE627Q52913260-B68F3955-82C2-4285-B250-ECE9CF3E0841Q52913704-88D2CE93-8FF7-4B0B-B3DB-DCA99BC41F9AQ53816699-13D3A9A5-F0E1-49A5-AE60-7A6343B298F4
P2860
Prostate cancer screening: what we know and what we need to know.
description
1993 nî lūn-bûn
@nan
1993年の論文
@ja
1993年学术文章
@wuu
1993年学术文章
@zh
1993年学术文章
@zh-cn
1993年学术文章
@zh-hans
1993年学术文章
@zh-my
1993年学术文章
@zh-sg
1993年學術文章
@yue
1993年學術文章
@zh-hant
name
Prostate cancer screening: what we know and what we need to know.
@en
Prostate cancer screening: what we know and what we need to know.
@nl
type
label
Prostate cancer screening: what we know and what we need to know.
@en
Prostate cancer screening: what we know and what we need to know.
@nl
prefLabel
Prostate cancer screening: what we know and what we need to know.
@en
Prostate cancer screening: what we know and what we need to know.
@nl
P2093
P1476
Prostate cancer screening: what we know and what we need to know.
@en
P2093
P304
P356
10.7326/0003-4819-119-9-199311010-00009
P407
P577
1993-11-01T00:00:00Z